<DOC>
	<DOCNO>NCT02707757</DOCNO>
	<brief_summary>Anaemia dialysis patient require treatment frequent dose adjustment . There two current possible treatment anaemia iron erythropoietin stimulate agent ( ESA ) . Dosages medication currently guide patient 's ferritin level haemoglobin , marker know inaccurate . The current clinical protocol therefore tend towards overuse agent associated toxicity , reliance marker prevents retrospective assessment treatment responsiveness . This study design investigate factor predict agent would produce good response . Patients fall haemoglobin give treatment either iron increase dose ESA currently , allocate random rather poorly perform biochemical marker . The iron treat ESA treat group analyse factor predict response</brief_summary>
	<brief_title>Treatment Response Dialysis Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>All prevalent haemodialysis patient Imperial Renal Transplant Centre eligible inclusion dialysis 3 month Patients bone marrow disorder , active infection active malignancy exclude nonrenal cause anaemia . Patients unable give inform consent also include within study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Haemodialysis</keyword>
	<keyword>Anaemia</keyword>
	<keyword>Iron</keyword>
	<keyword>Erythropoeitin stimulating agent</keyword>
</DOC>